Save up to 30% on Elsevier print and eBooks with free shipping. No promo code needed.
Save up to 30% on print and eBooks.
Anticancer Treatments and Cardiotoxicity
Mechanisms, Diagnostic and Therapeutic Interventions
1st Edition - November 11, 2016
Editors: Patrizio Lancellotti, Jose L Zamorano, Maurizio Galderisi
Language: English
Hardback ISBN:9780128025093
9 7 8 - 0 - 1 2 - 8 0 2 5 0 9 - 3
eBook ISBN:9780128026472
9 7 8 - 0 - 1 2 - 8 0 2 6 4 7 - 2
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiother…Read more
Purchase options
LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.
This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.
Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients
Written by world-leading experts in the field of cardiotoxicity
Includes high-quality images, case studies, and test questions
Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
Professionals and graduate students in the fields of toxicology and cardiology research; Oncologists; Cardiologists; Clinicians
List of Contributors
Foreword
Preface
Preamble
How Big Is the Problem? The Oncologist’s View
How Big Is the Problem? The Cardiologists’ View
Section I: General Considerations
Chapter 1. Epidemiology and Trend of Prognosis in Cancer Patients
Abstract
References
Chapter 2. Categories of Anticancer Treatments
Abstract
Further Reading
Chapter 3. Classification by Mechanisms of Cardiotoxicity
Abstract
Introduction
Type I Cardiotoxicity
Type II Cardiotoxicity
Cardiotoxicity Induced By TKI, VEGF Inhibitors
Cardiotoxicity Induced by Other Chemotherapy Drugs
References
Chapter 4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?
Abstract
References
Chapter 5. The Impact of Radiotherapy
Abstract
Mechanisms of Toxicity
Factors Modulating Radiosensitivity
References
Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart
Chapter 6. Lessons From Preclinical Models
Abstract
References
Chapter 7. Genetic and Epigenetic Risk Factors
Abstract
Anthracyclines
Trastuzumab
Radiotherapy
References
Chapter 8. Changes of Myocardial Structure and Function
Abstract
Introduction
Anthracyclines
Clinical Aspects
Target Therapy
ErbB2 Inhibitors
Monoclonal Antibodies
Proteasome Inhibitors
Angiogenesis Inhibitors
Clinical Aspects
Other Tyrosine Kinase Inhibitors
Radiation-Induced Cardiomyopathy
Conclusions
References
Chapter 9. Alteration of Heart Valves
Abstract
Introduction
Pathology of Radiation-Induced Valvular Disease
Risk Factors and Clinical Manifestations
Monitoring, Diagnosis, and Management of RIVD
Conclusions
References
Chapter 10. Pericardial Damage
Abstract
References
Chapter 11. Effects of Radiotherapy on Vessels and Coronary Arteries
Abstract
Pathophysiology and Histopathology
Coronary Artery Disease
References
Chapter 12. Cardiac Conduction Disturbances
Abstract
Physiopathologic Mechanisms
Clinical Manifestations
References
Section III: Cardiovascular Complications of Cancer Treatments
Chapter 13. Cardiac Rhythm Disturbances
Abstract
Introduction
Rhythm Disturbances Associated With Neoplasms
Rhythm Disturbances Secondary to Cancer Therapeutics
Rhythm Disturbances Secondary to Radiotherapy
QT Prolongation in the Cancer Patient
Interaction Between Supportive Therapy and Antiarrhythmic Medication
Bradycardia, Sinus Node Dysfunction and Conduction Defects
References
Chapter 33. Anticoagulation in Cancer Patients
Abstract
Therapeutic Anticoagulation
Prophylactic Anticoagulation
References
Chapter 34. New Drugs: The Beneficial Effects of Ranolazine
Abstract
Ranolazine: Mechanisms of Action
Rationale for the Use of Ranolazine to Protect From Anticancer Drugs
Basic and Clinical Researchers on the Use of Ranolazine in the Cancer Setting
References
Chapter 35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients
Abstract
Management of Patients With CAD and Cancer
Percutaneous Revascularization
Surgical Revascularization
Conclusion
References
Chapter 36. Focus on the Patient With Known Cardiac Disease
Abstract
Patients with cancer and previous known cardiac disease
Pre- and Peri-Operative Management of Patients with Cancer and Known Cardiac Disease
Conclusion
References
Chapter 37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients
Abstract
The Concept of Cardio-Oncology
The Importance of a Preliminary CV Risk Assessment in Cancer Patients
The Role of a Baseline CV Examination
The Role of a Cardiologic Follow-Up During Cancer Therapy
Cardiologic Follow-Up of Cancer Survivors After Therapy Completion
References
Section VIII: Future Research Priorities
Chapter 38. Pharmacogenomics Screening
Abstract
Pharmacogenomics: Background
Genetic Determinants of Anthracycline-Induced Cardiotoxicity
Genetic Determinants of Cardiotoxicity of Targeted Therapies
Conclusions
References
Chapter 39. Cardiac Monitoring During Clinical Trials
Abstract
Introduction
Phased Study Design
Careful Patient Selection
Cautious Cardiac Monitoring
Clear Stopping Rules (Interruption and Discontinuation)
Sequential Schemes of Anthracycline–Trastuzumab Administration
Alternative Schemes
Conclusion and Perspectives for Cardiac Monitoring and Management
References
Chapter 40. Preventive Therapy
Abstract
Dexrazoxane
Statins
Thalidomide
Metformin
References
Chapter 41. Cardiotoxicity: Future Research Directions
Abstract
How to Predict the Risk of CTRCD
How to Improve Therapeutic Strategies to Reduce Cardiotoxicity
References
Multiple Choice Questions
Index
No. of pages: 470
Language: English
Edition: 1
Published: November 11, 2016
Imprint: Academic Press
Hardback ISBN: 9780128025093
eBook ISBN: 9780128026472
PL
Patrizio Lancellotti
Patricio Lancellotti is head of the intensive care cardiology unit at the University of Liège Hospital Center and Professor of Clinical Medicine at the University of Liège. His research, conducted at Professor Luc Piérard's department of cardiology, has led to significant progress in the care of patients suffering from functional mitral insufficiency, a pathology often underestimated clinically yet weighing heavily on the prognosis. He has 300 peer-reviewed articles and an H-index = 40.
Affiliations and expertise
Professor of Cardiology, University of Liège, Liège, Belgium
JZ
Jose L Zamorano
José Luis Zamorano is Professor of Medicine and Head of Cardiology at the University Complutense in Madrid and Director of the Cardiovascular Institute at the University Clinic San Carlos, Madrid. His key research interests include ischemic heart disease, cardiovascular risk factors and imaging modalities. Professor Zamorano is President Elect of the European Association of Echocardiography (EAE) and President of the Working Group on Non-invasive Diagnostic Imaging of the Spanish Society of Cardiology. He serves on numerous Editorial Boards, including the European Journal of Echocardiography, the American Society of Echocardiography and the European Heart Journal. He has authored over 400 articles for peer-reviewed journals and has an H-index = 57.
Affiliations and expertise
Professor and Head of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain
MG
Maurizio Galderisi
Maurizio Galderisi, is Associate Professor of Cardiology and Clinical Director at Federico II University Hospital in Italy. His research interests include cardiac function, heart failure, arterial hypertension, tissue Doppler and strain rate imaging, coronary flow reserve. He has served as editor of one book and author of 10 chapters in various cardiologic books. He is the author or co-author of 250 articles on international peer-reviewed indexed journals, with an H-index = 38. He has been an invited speaker at more than 70 major national and international meetings and holds scientific association membership with Società Italiana di Cardiologia (SIC), Società Italiana di Ecografia Cardiovascolare (SIEC), European Association of Echocardiography (EAE), and the American Society of Echocardiography (ASE).
Affiliations and expertise
Associate Professor of Cardiology, Clinical Director, Federico II University Hospital, Italy
Read Anticancer Treatments and Cardiotoxicity on ScienceDirect